Corrado Cittanti

Ferrara, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Diagnostic accuracy of 18F-FDG PET/CT in muscle-invasive bladder cancer: rationale and design of the MIBC-PET study.

Diagnostic accuracy of 18F-FDG PET/CT in muscle-invasive bladder cancer: rationale and design of the MIBC-PET study.

Journal: Frontiers in medicine

Published: January 20, 2026

The Value of FDG PET/CT in Penile Cancer: An Update.

The Value of FDG PET/CT in Penile Cancer: An Update.

Journal: Seminars in nuclear medicine

Published: November 01, 2025

Emerging need of dosimetry in radioligand therapy: a feasible method tested in a large cohort of patients affected by neuroendocrine neoplasms.

Emerging need of dosimetry in radioligand therapy: a feasible method tested in a large cohort of patients affected by neuroendocrine neoplasms.

Journal: EJNMMI research

Published: May 23, 2025

Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer.

Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer.

Journal: Molecular diagnosis & therapy

Published: April 29, 2025

68Ga-Trivehexin: Current Status of αvβ6-Integrin Imaging and Perspectives.

68Ga-Trivehexin: Current Status of αvβ6-Integrin Imaging and Perspectives.

Journal: Cancers

Published: April 08, 2025

The Role of Radiomics and Artificial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness.

The Role of Radiomics and Artificial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness.

Journal: Journal of clinical medicine

Published: March 08, 2025

Radioligand Therapy with Radiolabeled Somatostatin Analogues in Metastatic Bronchial Carcinoid: an Impressive Response.

Radioligand Therapy with Radiolabeled Somatostatin Analogues in Metastatic Bronchial Carcinoid: an Impressive Response.

Journal: Nuclear medicine and molecular imaging

Published: February 12, 2025

Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma.

Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma.

Journal: Biomolecules

Published: October 31, 2024

18F-FDG PET/CT radiomic analysis and artificial intelligence to predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients.

18F-FDG PET/CT radiomic analysis and artificial intelligence to predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients.

Journal: La Radiologia medica

Published: August 20, 2024

Radioligand therapy in sympathetic-adrenal-medullary axis tumors: state of art and perspectives.

Radioligand therapy in sympathetic-adrenal-medullary axis tumors: state of art and perspectives.

Journal: Endocrine

Published: July 31, 2024

Is There a Role for FAPI PET in Urological Cancers?

Is There a Role for FAPI PET in Urological Cancers?

Journal: Molecular diagnosis & therapy

Published: July 26, 2024

ML Models Built Using Clinical Parameters and Radiomic Features Extracted from 18F-Choline PET/CT for the Prediction of Biochemical Recurrence after Metastasis-Directed Therapy in Patients with Oligometastatic Prostate Cancer.

ML Models Built Using Clinical Parameters and Radiomic Features Extracted from 18F-Choline PET/CT for the Prediction of Biochemical Recurrence after Metastasis-Directed Therapy in Patients with Oligometastatic Prostate Cancer.

Journal: Diagnostics (Basel, Switzerland)

Published: May 16, 2024

Showing 1-12 of 52

Last Updated: 09/26/2026